The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.

Here & Now’s Peter O’Dowd spoke with Sarah Zhang, a reporter for The Atlantic, about how people are searching the web and using the app Telegram to buy next-generation GLP-3 drugs not yet approved by ...